Advertisement
MLSS vs SRDX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MLSS is a Hold and SRDX is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MLSS’s FA Score shows that 0 FA rating(s) are green whileSRDX’s FA Score has 0 green FA rating(s).
- MLSS’s FA Score: 0 green, 5 red.
- SRDX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MLSS’s TA Score shows that 3 TA indicator(s) are bullish while SRDX’s TA Score has 5 bullish TA indicator(s).
- MLSS’s TA Score: 3 bullish, 4 bearish.
- SRDX’s TA Score: 5 bullish, 6 bearish.
Price Growth
MLSS (@Pharmaceuticals: Other) experienced а -2.65% price change this week, while SRDX (@Medical/Nursing Services) price change was +56.74% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +1.44%. For the same industry, the average monthly price growth was +1.60%, and the average quarterly price growth was +7.03%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +0.02%. For the same industry, the average monthly price growth was -4.87%, and the average quarterly price growth was +6.23%.
Reported Earning Dates
MLSS is expected to report earnings on Mar 27, 2026.
SRDX is expected to report earnings on Feb 10, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+1.44% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (+0.02% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| MLSS | SRDX | MLSS / SRDX | |
| Capitalization | 29.8M | 592M | 5% |
| EBITDA | -6.83M | -2.74M | 249% |
| Gain YTD | -60.448 | 4.571 | -1,323% |
| P/E Ratio | N/A | 43.23 | - |
| Revenue | 9.08M | 121M | 8% |
| Total Cash | 1.27M | 32.7M | 4% |
| Total Debt | 1.09M | 32.6M | 3% |
MLSS | SRDX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 33 | 33 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 98 Overvalued | 93 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 97 | |
SMR RATING 1..100 | 99 | 94 | |
PRICE GROWTH RATING 1..100 | 94 | 38 | |
P/E GROWTH RATING 1..100 | 100 | 92 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SRDX's Valuation (93) in the Medical Specialties industry is in the same range as MLSS (98). This means that SRDX’s stock grew similarly to MLSS’s over the last 12 months.
SRDX's Profit vs Risk Rating (97) in the Medical Specialties industry is in the same range as MLSS (100). This means that SRDX’s stock grew similarly to MLSS’s over the last 12 months.
SRDX's SMR Rating (94) in the Medical Specialties industry is in the same range as MLSS (99). This means that SRDX’s stock grew similarly to MLSS’s over the last 12 months.
SRDX's Price Growth Rating (38) in the Medical Specialties industry is somewhat better than the same rating for MLSS (94). This means that SRDX’s stock grew somewhat faster than MLSS’s over the last 12 months.
SRDX's P/E Growth Rating (92) in the Medical Specialties industry is in the same range as MLSS (100). This means that SRDX’s stock grew similarly to MLSS’s over the last 12 months.
| MLSS | SRDX | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 57% |
| Stochastic ODDS (%) | 2 days ago 83% | 2 days ago 69% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 75% |
| MACD ODDS (%) | 2 days ago 80% | 2 days ago 67% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 66% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 67% |
| Advances ODDS (%) | 18 days ago 79% | 2 days ago 65% |
| Declines ODDS (%) | 3 days ago 90% | 22 days ago 69% |
| BollingerBands ODDS (%) | 2 days ago 85% | 2 days ago 63% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 57% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| QTERX | 13.43 | -0.15 | -1.10% |
| AQR Emerging Multi-Style II R6 | |||
| PRERX | 27.23 | -0.31 | -1.13% |
| Principal Real Estate Securities R3 | |||
| DRISX | 18.26 | -0.26 | -1.40% |
| North Square Small Cap Value I | |||
| MUECX | 36.85 | -0.58 | -1.55% |
| MFS Blended Research Core Equity C | |||
| SMIPX | 14.73 | -0.41 | -2.71% |
| Saratoga Mid Capitalization I | |||
MLSS and
Correlation & Price change
A.I.dvisor tells us that MLSS and ANGO have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MLSS and ANGO's prices will move in lockstep.
| Ticker / NAME | Correlation To MLSS | 1D Price Change % | ||
|---|---|---|---|---|
| MLSS | 100% | +6.03% | ||
| ANGO - MLSS | 27% Poorly correlated | -2.84% | ||
| ESTA - MLSS | 26% Poorly correlated | +2.47% | ||
| SRDX - MLSS | 26% Poorly correlated | +0.15% | ||
| QDEL - MLSS | 25% Poorly correlated | -1.81% | ||
| GKOS - MLSS | 25% Poorly correlated | -0.86% | ||
More | ||||
SRDX and
Correlation & Price change
A.I.dvisor tells us that SRDX and BDX have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SRDX and BDX's prices will move in lockstep.
| Ticker / NAME | Correlation To SRDX | 1D Price Change % | ||
|---|---|---|---|---|
| SRDX | 100% | +0.15% | ||
| BDX - SRDX | 32% Poorly correlated | +0.48% | ||
| ALGN - SRDX | 31% Poorly correlated | -1.60% | ||
| SIBN - SRDX | 29% Poorly correlated | -4.11% | ||
| BLCO - SRDX | 29% Poorly correlated | -5.48% | ||
| ATRC - SRDX | 28% Poorly correlated | -4.08% | ||
More | ||||